Adalimumab for sight-threatening uveitis in Behçet's disease

Authors:

Abstract
Aims To describe the clinical outcome of three patients with Behçet's disease maintained on infliximab who were switched to adalimumab therapy. Methods Case note review. Main outcome measure was recurrence of uveitis. Results All patients remained free of recurrence with stable visual acuities. Conclusions Adalimumab appears to maintain disease remission in Behçet's disease.